Results 21 to 30 of about 153,721 (218)

Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?

Frontiers in Immunology, 2022
Immune checkpoint inhibitor (ICI) is one of the most important tumor treatment methods. Although the therapeutic efficiency of immune checkpoint inhibitor mono-therapy is limited, the combination of chemotherapy plus immune checkpoint inhibitors has ...
Xinye Qian, Xinye Qian, Wang Hu, Wang Hu, Jun Yan, Jun Yan   +5 more
doaj   +1 more source

Immune Checkpoint Inhibitor Therapy Associated Hypophysitis

Clinical Medicine Insights: Endocrinology and Diabetes, 2015
Ipilimumab is a monoclonal antibody directed against CTLA4 T-lymphocyte antigen used as cancer therapy. Immune-related adverse events are common side effects and may include hypophysitis-related hypopituitarism. The clinical features of six patients with
Moeber Mahzari, Dora Liu, Amel Arnaout, Heather Lochnan   +3 more
doaj   +2 more sources

Avelumab-Induced Scleroderma in a Patient with Metastatic Squamous Cell Carcinoma of the Lung

Case Reports in Dermatological Medicine, 2022
Immune checkpoint inhibitors are associated with a spectrum of cutaneous immune-related adverse events. While maculopapular eruptions are the most common cutaneous adverse event, scleroderma can rarely develop.
Jeffrey L. Dobrzynski, Blake E. Vest, Brian L. Swick   +2 more
doaj   +1 more source

Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report

Journal of Medical Case Reports, 2018
Background Novel immune checkpoint inhibitors have been often utilized for different types of malignancies as salvage therapy with varying success. One obstacle to immune checkpoint inhibitor use is the higher incidence of immune-mediated side effects ...
Linh Ngo, Eric Miller, Peter Valen, Elie Gertner   +3 more
doaj   +1 more source

Efficacy and Safety of Immune Checkpoint Inhibitors Therapy on Advanced Gastric Cancer or Gastroesophageal Junction Cancer: A Meta-analysis

Zhongliu Fangzhi Yanjiu, 2021
Objective To systematically evaluate the efficacy and safety of immune checkpoint inhibitors in the treatment of advanced gastric cancer or gastroesophageal junction cancer (GC/GEJC).
SHAN Yujie, LIANG Ping, LYU Yalei, WANG Long, ZHANG Xiaolin, SHAN Baoen   +5 more
doaj   +1 more source

Unsuccessful rechallenge with nivolumab in a patient with advanced non‐small cell lung cancer who had a 6‐year complete response and treatment‐free period: Case report

Respirology Case Reports
Several predictive factors of immune checkpoint inhibitor response have been reported, but there has not been sufficient exploration of which patients benefit from immune checkpoint inhibitor rechallenge.
Toshiaki Takakura, Hiroaki Akamatsu, Atsushi Washioka, Eriko Murakami, Ryota Shibaki, Toshio Shimizu, Yasuhiro Koh, Nobuyuki Yamamoto   +7 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature

Respiratory Medicine Case Reports, 2019
Immune checkpoint inhibitors are known to cause a variety of immune-related adverse events, including pneumonitis. When symptomatic, treatment typically consists of temporary or permanent cessation of the checkpoint inhibitor and several weeks of ...
Camille R. Petri, Rushad Patell, Felipe Batalini, Deepa Rangachari, Robert W. Hallowell   +4 more
doaj   +1 more source

Immune Checkpoint Inhibitor Induced Hepatitis Injury:

Translation, 2023
Please view the PDF to see the formatted meeting abstract.  
Danae Hamouda
doaj   +1 more source

Epigenetic reprogramming of lineage switching in cancer

FEBS Letters, EarlyView.
Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı, Burcu Akman, Ezgi Bağırsakçı, Nese Atabey, Serap Erkek‐Ozhan   +4 more
wiley   +1 more source